Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products.
Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products.
复制标题
针对肺癌中PI3K/AKT/mTOR信号通路的研究进展:潜在药物与天然产物概述
DOI:
10.3390/molecules26134100
复制
发表时间:
2021-07-05
期刊:
影响因子:
--
通讯作者:
Pongrakhananon V
中科院分区:
文献类型:
--
作者:
Iksen;Pothongsrisit S;Pongrakhananon V
Lung cancer is one of the most common cancers and has a high mortality rate. Due to its high incidence, the clinical management of the disease remains a major challenge. Several reports have documented a relationship between the phosphatidylinositol-3-kinase (PI3K)/ protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) pathway and lung cancer. The recognition of this pathway as a notable therapeutic target in lung cancer is mainly due to its central involvement in the initiation and progression of the disease. Interest in using natural and synthetic medications to target these signaling pathways has increased in recent years, with promising results in vitro, in vivo, and in clinical trials. In this review, we focus on the current understanding of PI3K/AKT/mTOR signaling in tumor development. In addition to the signaling pathway, we highlighted the therapeutic potential of recently developed PI3K/AKT/mTOR inhibitors based on preclinical and clinical trials.
登录
查看更多内容
影响因子:
64.5
作者:
Brunet, A;Bonni, A;Greenberg, ME
通讯作者:
Greenberg, ME
影响因子:
2.6
作者:
Arcaro A;Guerreiro AS
通讯作者:
Guerreiro AS
影响因子:
--
作者:
Cai Y;Dodhia S;Su GH
通讯作者:
Su GH
影响因子:
5
作者:
Attar-Schneider, Oshrat;Drucker, Liat;Gottfried, Maya
通讯作者:
Gottfried, Maya
影响因子:
12.4
作者:
Adams JM;Cory S
通讯作者:
Cory S